JoVE Logo
Faculty Resource Center

Sign In

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

DOI :

10.3791/3445-v

16:57 min

February 14th, 2012

February 14th, 2012

25,426 Views

1Department of Pharmaceutical Biosciences, Uppsala University, 2Department of Chemical and Biological Engineering, Chalmers University of Technology

Dopamine replacement pharmacotherapy using L-DOPA is the most commonly used symptomatic treatment of Parkinson’s disease, but is accompanied by side effects including involuntary abnormal movements, termed dyskinesia 1. Here, a protocol for MALDI imaging mass spectrometry is presented that detects changes in rat brain neuropeptide levels related to dyskinesia.

Tags

MALDI Imaging Mass Spectrometry

-- Views

Related Videos

article

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

article

Skin Punch Biopsy Explant Culture for Derivation of Primary Human Fibroblasts

article

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

article

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

article

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

article

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

article

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

article

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

article

Imaging Metals in Brain Tissue by Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS)

article

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved